BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

656 related articles for article (PubMed ID: 17918195)

  • 21. Clinical trial designs based on sequential conditional probability ratio tests and reverse stochastic curtailing.
    Tan M; Xiong X; Kutner MH
    Biometrics; 1998 Jun; 54(2):682-95. PubMed ID: 9629648
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Optimal conditional error functions for the control of conditional power.
    Brannath W; Bauer P
    Biometrics; 2004 Sep; 60(3):715-23. PubMed ID: 15339294
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A practical comparison of group-sequential and adaptive designs.
    Kelly PJ; Sooriyarachchi MR; Stallard N; Todd S
    J Biopharm Stat; 2005; 15(4):719-38. PubMed ID: 16022175
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sample size re-estimation in group-sequential response-adaptive clinical trials.
    Morgan CC
    Stat Med; 2003 Dec; 22(24):3843-57. PubMed ID: 14673942
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A group-sequential design for clinical trials with treatment selection.
    Stallard N; Friede T
    Stat Med; 2008 Dec; 27(29):6209-27. PubMed ID: 18792085
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Exact statistical inference for group sequential trials.
    Lin DY; Wei LJ; DeMets DL
    Biometrics; 1991 Dec; 47(4):1399-408. PubMed ID: 1786325
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nonparametric confidence intervals for Tmax in sequence-stratified crossover studies.
    Willavize SA; Morgenthien EA
    Pharm Stat; 2008; 7(1):9-19. PubMed ID: 17256803
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Confidence intervals for a normal mean following a group sequential test.
    Chang MN
    Biometrics; 1989 Mar; 45(1):247-54. PubMed ID: 2720054
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The advantages and disadvantages of adaptive designs for clinical trials.
    Bauer P; Brannath W
    Drug Discov Today; 2004 Apr; 9(8):351-7. PubMed ID: 15081962
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Flexible design of two-stage adaptive procedures for phase III clinical trials.
    Koyama T
    Contemp Clin Trials; 2007 Jul; 28(4):500-13. PubMed ID: 17307399
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Statistical considerations for testing multiple endpoints in group sequential or adaptive clinical trials.
    Hung HM; Wang SJ; O'Neill R
    J Biopharm Stat; 2007; 17(6):1201-10. PubMed ID: 18027226
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Confidence intervals and sample sizes.
    Grieve AP
    Biometrics; 1991 Dec; 47(4):1597-602; discussion 1602-3. PubMed ID: 1786333
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A two stage conditional power adaptive design adjusting for treatment by covariate interaction.
    Ayanlowo AO; Redden DT
    Contemp Clin Trials; 2008 May; 29(3):428-38. PubMed ID: 18053774
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Conditional and unconditional confidence intervals following a group sequential test.
    Fan X; DeMets DL
    J Biopharm Stat; 2006; 16(1):107-22. PubMed ID: 16440840
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficient group sequential designs when there are several effect sizes under consideration.
    Jennison C; Turnbull BW
    Stat Med; 2006 Mar; 25(6):917-32. PubMed ID: 16220524
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The impact of stopping rules on heterogeneity of results in overviews of clinical trials.
    Hughes MD; Freedman LS; Pocock SJ
    Biometrics; 1992 Mar; 48(1):41-53. PubMed ID: 1581492
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multiplicity and flexibility in clinical trials.
    Brannath W; Koenig F; Bauer P
    Pharm Stat; 2007; 6(3):205-16. PubMed ID: 17674349
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Issues in designing flexible trials.
    Posch M; Bauer P; Brannath W
    Stat Med; 2003 Mar; 22(6):953-69. PubMed ID: 12627412
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluating the adaptive performance of flexible sample size designs with treatment difference in an interval.
    Liu GF; Zhu GR; Cui L
    Stat Med; 2008 Feb; 27(4):584-96. PubMed ID: 17634972
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Methods for one-sided testing of the difference between proportions and sample size considerations related to non-inferiority clinical trials.
    Dann RS; Koch GG
    Pharm Stat; 2008; 7(2):130-41. PubMed ID: 17526060
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.